Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Member News
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Related or similar articles
December 9, 2021
Bulfinch Leases 40,000 Square Feet to Labshares
BOSTON & NEWTON, Mass.--(BUSINESS WIRE)--The Bulfinch Companies, Inc. (Bulfinch), a commercial real estate and investment firm, and Labshares Newton today announced the expansion of the life science and biotech co-working incubator at Chapel Bridge..
Labshares News
March 13, 2019
Labshares Celebrates Grand Opening and Unveils Newly Expanded Shared Office and Lab Space in Newton
Labshares Newton's newly expanded facility features a cutting-edge lab and co-working space that can now accommodate up to 30 startups
Press Releases
.avif)
April 29, 2024
Lab Space Boston: Navigating Opportunities and Challenges
Hello, fellow science enthusiasts! If you're on the hunt for the perfect laboratory space in greater Boston and Cambridge, you've come to the right place. As experts in the field, we at Labshares know a thing or two about navigating the opportunities
Labshares News